Drug Profile
Research programme: anticancer antibodies - Genetastix
Alternative Names: Anti-CXCR4 antibody; Anti-IGF-r1 antibodyLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Genetastix Corporation
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)